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Introduction
Cancer metastasis is a multistep process characterised by 
local invasion, transport by the circulation, and survival 
and proliferation of metastasising cells in distant tissues. 
Similarities have been observed between the invasive and 
metastatic behaviour of cancer cells on the one hand and 
the long-distance migration of cells during development 
on the other. Epithelial cells usually form a mono- or 
multilayer on top of a basement membrane, and by lining 
the cavities and surfaces of the body, they form a pro-
tective barrier. Th   ese cells are tightly connected to each 
other by adhesion proteins (for example, E-cadherin), 
they express epithelial markers (for example, cytokera-
tins), and they are apico-basally polarised. Together with 
the extracellular matrix (ECM), mesen  chymal cells ﬁ  ll the 
interstitial spaces and are a source of growth factors. 
Mesenchymal cells lack cell-cell contacts, express mesen-
chymal markers such as vimentin, and exhibit migratory 
behaviour. During epithelial-to-mesenchymal transition 
(EMT), epithelial cells lose their epithelial features and 
acquire a ﬁ   broblast-like morphology, with cytoskeletal 
reorganisation, upregu  lation of mesenchymal markers, 
and enhancement of motility, invasiveness and metastatic 
capabilities [1,2]. Th   erefore, reactivation of an embryonic 
EMT program could be the underlying mechanism of 
tumour invasion. At distant sites, cancer cells can 
under  go the reverse process, a mesenchymal-to-epithelial 
transi tion  (MET).  Th  is is a transient phenomenon in 
which cancer cells reacquire epithelial characteristics 
once the invasion step is ﬁ  nished [1,3]. Understanding 
these processes is crucial because metastasis is a promi-
nent cause of cancer-related death.
EMT has been studied extensively in cancer cell lines, 
but pathologists still question the occurrence of EMT in 
human cancer in vivo. By using diﬀ  erent mouse models of 
mammary cancers in combination with the cre-Rosa26LoxP
reporter, Trimboli and colleagues [4] provided strong evi-
dence for an EMT role in breast cancer. Approximately 
50% of the tumours from WAP-myc mice showed 
ﬁ  broblast-like cells of mammary epithelial origin adjacent 
to the tumour site, which proves the existence of early 
stages of EMT in vivo. Th   e occurrence of EMT in breast 
cancer  in vivo was illustrated by immunohisto  chemical 
analysis of human invasive breast carcinomas and carcino-
sarcomas [5]. Simultaneous upregulation of mesenchymal 
markers, such as vimentin and proteins involved in motility 
and ECM remodelling, together with down  regu  lation of 
epithelial markers such as E-cadherin, were predomi nant  in 
breast tumours with a basal-like pheno  type. Breast 
carcinosarcomas are supposed to have under  gone 
complete EMT and show a basal-like pheno  type, which 
suggests that EMT occurs in speciﬁ  c tumour subtypes [5].
Th   is review will focus mainly on the speciﬁ  c role of the 
transcription factors Snail1 (encoded by SNAI1) and 
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cancer. Snail1 is a zinc-ﬁ  nger transcription factor belong-
ing to the Snail superfamily and characterised by a 
strongly conserved carboxy-terminal region containing 
four to six C2H2-zinc ﬁ  ngers. Snail family members Snail1 
and Snail2 (Slug) act as transcriptional repressors when 
their ﬁ  ngers bind to E-box motifs (5’-CANNTG-3’) in 
target promoters, including the E-cadherin gene (CDH1) 
promoter. Snail1 plays an essential role during gastru-
lation and neural crest formation, which explains the 
death of Snail1 knock-out mice at the gastrula stage [6]. 
Mammals have two Twist-like proteins with strong 
structural homology. Twist proteins possess an evolu-
tionarily conserved basic helix-loop-helix domain, which 
allows protein-protein interaction with other basic helix-
loop-helix proteins. When Twist molecules dimerise, 
they bind to E-box sequences in target promoters [7]. 
Gene deletion experiments showed that Twist1 is impor-
tant for closure of the neural tube during embryogenesis 
[8]. On the other hand, the elevated expression of pro-
inﬂ  ammatory cytokines in Twist2 knock-out mice caused 
perinatal death [9]. In Drosophila, Snail1 acts as a 
repressor of ectodermal genes and Twist1 as a positive 
regulator of mesoderm-speciﬁ  c genes, and together they 
deﬁ   ne the borders between the mesoderm and the 
surrounding tissue [10]. Stable Snail1 knock-down in 
breast and skin carcinoma cell lines causes a partial MET 
with weak invasiveness and tumorigenicity, but these 
eﬀ  ects were not observed in Snail2 knock-down cells. 
Th   is suggests that Snail1 and Snail2 have complementary 
roles in the induction of tumour growth [11]. In human 
cancers, Twist1 has been linked to metastasis [12] and 
Snail1 to recurrence [13].
Snail1 and Twist1 during mammary gland 
development
Most vertebrate organs are patterned during embryo-
genesis and maintain their basic structure throughout 
adult life, but the structure of breast tissue in repro-
ductive females changes continuously [14]. Before birth, 
the speciﬁ   ed mammary epithelium invades from the 
nipple into the fat pad to form a small, branched ductal 
network. Snail1 and Snail2 control expression of 
aromatase, which converts androgens to oestrogens. Th  e 
latter are necessary for ductal outgrowth, and so SNAI 
genes might play a role in ductal network development 
[15]. Th   e release of ovarian hormones in puberty causes 
the distal ends of the mammary ducts to swell into bulbous 
structures composed of multiple layers of cuboidal 
epithelial cells called terminal end buds (Figure  1)  [16]. 
Experimental evidence indicating a role for Snail family 
members during acini diﬀ  erentiation is very limited. In 
this respect, mammary epithelial MCF-10A cells 
cultivated on matrigel form acinar structures with 
characteristics found in glandular epithelium in vivo [17]. 
Gene expression analysis in this cellular model system 
revealed substantial amounts of Snail2 and E-cadherin 
mRNA, but very little Snail1 mRNA (Foubert E, Berx G, 
unpublished observation). Similar results were obtained 
by Côme and colleagues using human mammary 
epithelial cells cultivated on matrigel, which suggests that 
Snail2 has an active role during the lobuloalveolar phase 
[18]. Th   e mammary gland reaches its ﬁ  nal developmental 
stage during pregnancy and lactation. Reproductive 
hormones induce the expansion and terminal 
diﬀ   erentiation of the mammary epithelium into 
secretory, milk-producing, lobular alveoli, while large fat 
cells dediﬀ   erentiate into tiny adipocytes [19]. During 
involution, the mammary gland regresses due to 
apoptosis of alveolar epithelial cells and remodelling of 
the basement membrane, and this restores the breast to 
its previous state. Snail2 has an anti-apoptotic function 
and might be involved in the ﬁ  nal stages of this process as 
a break to stop involution [18].
Many processes during mammary gland development 
have some features of tumour progression, such as inva-
sion, reinitiation of cell proliferation, resistance to apop-
tosis, and angiogenesis. Inhibition of stromal regulators 
or secreted growth and diﬀ  erentiation factors disturbs 
the interaction between the epithelium and ECM. Th  is 
disruption can induce and promote breast cancer 
(Figure 1).
Snail1 and Twist1 as criteria in breast cancer 
classifi  cation?
Breast cancer can be classiﬁ  ed on the basis of diﬀ  erent 
criteria. Classically, two main histological subgroups are 
deﬁ  ned morphologically, ductal and lobular carcinomas, 
which together represent 90% of all breast cancers. 
Ductal carcinoma in situ is the most common type of 
non-invasive breast cancer and arises inside the milk 
ducts, whereas lobular carcinoma in situ is characterised 
by abnormal cell growth in the lobules. When tumour 
cells invade the surrounding tissue and give rise to 
metastasis, ductal carcinoma in situ can progress to 
invasive ductal carcinoma, and lobular carcinoma in situ 
to lobular carcinoma [20]. Ductal carcinoma in situ and 
lobular carcinoma in situ can be distinguished by the 
expression of E-cadherin. Positive but heterogeneous 
E-cadherin expression is observed in invasive ductal 
carcinomas. In contrast, there is often no E-cadherin 
expression in inﬁ   ltrating lobular carcinomas due to 
somatic mutations in CDH1, loss of heterozygosity, or 
CDH1 promoter methylation [21].
At least ﬁ  ve molecular subtypes of breast cancer can be 
distinguished by their gene expression proﬁ  les: luminal 
A, luminal B, normal breast-like, HER-2+/ER-, and basal-
like [5,22]. Luminal tumours are positive for the 
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markers such as cytokeratin 8 and 18. Based on 
diﬀ  erences in histological grade and prognosis, luminal 
tumours are classiﬁ  ed as luminal A or luminal B. Th  e 
clinical signiﬁ    cance of normal breast-like tumours is still 
questionable because these lesions consistently cluster 
together with samples of ﬁ   broadenomas and normal 
breast samples [22]. Th   e contribution of the ER pathway 
to EMT is well described as the ER status has an impact 
on E-cadherin biosynthesis. In response to oestrogen 
signalling, ER indirectly activates MTA3 (metastasis 
associated 1 family, member 3), which forms a 
transcriptional co-repressor complex with Mi-2/NuRD. 
One direct function of this complex is to inhibit Snail1, 
which leads indirectly to transcriptional activation of E-
cadherin [23]. More recently, it was shown that the ER 
pathway can regulate Snail2 expression. Ligand-activated 
ERα forms a trans  criptional inhibitory complex with 
histone deacetylase 1 (HDAC1) and the nuclear receptor 
corepressor (N-CoR), which leads to repression of the 
Snail2 promoter and results in E-cadherin expression. 
Alternatively, Snail2 expression can be inhibited by 
glycogen synthase kinase 3-beta inactivation through 
phosphoinositide 3-kinase (PI3K)/AKT activation upon 
ERα activity [24].
ER-negative tumours are composed of HER-2 tumours 
(which overexpress HER-2 and genes associated with the 
HER-2 pathway) and the basal-like subgroups. Th  ese 
tumours express genes usually expressed in myo-
epithelium of the normal mammary gland, such as basal 
cytokeratins and epidermal growth factor receptor. Th  ey 
are usually characterised by high histological grade, 
resistance to chemotherapy, and poor prognosis [5,22]. 
Basal-like tumours are often incorrectly described in the 
Figure 1. Role of Snail1 and Twist1 during mammary gland development and breast cancer progression. In females, release of ovarian 
hormones induces further development of the mammary gland. Snail1 and Snail2 control aromatase expression, indicating that they have a role in 
development of the ductal network. Somatic mutations and/or aberrant expression of oncogenes can cause proliferation of mammary epithelial 
cells. During malignant cancer progression, Snail1 induces an epithelial-to-mesenchymal transition (EMT) of epithelial breast cancer cells, which 
grants them invasive and migratory capacities. Twist1 plays a role in the development of distant metastasis by prompting cancer cells to enter the 
bloodstream. At distant organs, these cells undergo a mesenchymal-to-epithelial transition (MET).
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progesterone receptor and HER-2) [25]. Indeed, most 
triple-negative cancers have a basal-like phenotype, but 
several do not express basal markers. On the other hand, 
a small sub  group of basal-like cancers expresses either 
hormone receptors or HER-2 [26].
Immunohistochemical analysis illustrated that aggres-
sive, poorly diﬀ  erentiated tumours usually express basal 
markers typical of the basal-like phenotype [5]. Statistical 
analysis of breast adenocarcinoma samples correlated 
high  ZEB1 expression with clinicopathological features 
such as poorly diﬀ  erentiated tumours, meta  stasis, and 
poor survival. [27]. Microarray analysis revealed Snail2 
expression in basal-like breast cancer cell lines [28]. It 
was demonstrated that tumours expressing high levels of 
SNAI2 mRNA have a basal-like phenotype [29]. Th  ese 
data indicate that EMT preferentially occurs in more 
aggressive breast tumours of the basal phenotype.
Interplay of transcription factors in the control of 
EMT in breast cancer
One key molecular change in EMT is E-cadherin down-
regulation, which results in reduction of cell-cell 
adhesion and destabilisation of the epithelial architecture. 
Several transcription factors, so-called EMT inducers, 
act as transcriptional repressors of E-cadherin and 
directly modulate the expression of many genes involved 
in cancer invasion and metastasis, consequently promot-
ing EMT in vitro [30]. Th   ese transcription factors include 
members of the Snail family (SNAI1/Snail1 and SNAI2/
Snail2/Slug) and ZEB (zinc ﬁ  nger E-box binding homeo-
box) family (ZEB1/δEF1 and ZEB2/SIP1), basic helix-
loop-helix factors, such as E12/E47 and Twist1, and the 
recently identiﬁ   ed factors CBF-A (CArG box-binding 
factor-A), FOXC2 (forkhead 1), HOXB7 (homeobox gene 
B7), Goosecoid, and KLF8 (Krüppel-like factor 8) 
[2,30,31]. Most of these transcription factors have been 
shown to bind and repress the CDH1 promoter, but 
direct interaction of Twist1 with this promoter has not 
been proven [12,32].
Peinado and colleagues [33] suggested a model in 
which diﬀ  erent E-cadherin repressors participate during 
EMT/invasion. In this model, Snail1 and ZEB2 play a role 
in inducing the ﬁ  rst EMT steps that lead to the initiation 
of the invasive process, whereas Snail2, E47 and ZEB1 
favour the maintenance of the migratory, invasive pheno-
type, and Twist1 has a critical role in the development of 
distant metastases by prompting cancer cells to enter the 
bloodstream [12]. EMT is a transient, reversible process 
and most likely occurs only in small groups of cells or 
isolated cells in the invasive areas of tumours. Tumour 
cells undergoing partial EMT, and so exhibiting only 
some features of the developmental program, are there-
fore diﬃ     cult to distinguish from tumour-associated 
ﬁ  broblasts sharing similar characteristics. Nevertheless, 
many potential markers have been described for 
monitor  ing EMT in tissue samples and in biological 
ﬂ  uids [34].
In addition, other recent ﬁ   ndings provide further 
evidence for the involvement of diﬀ  erent EMT mecha-
nisms in breast cancer, including signalling pathways, the 
micro-environment, and the newly discovered develop-
mental proteins acting upstream of EMT inducers. 
Several classical signalling cascades (transforming 
growth factor (TGF)-β, Wnt, and receptor tyrosine 
kinase signalling) that lead to the expression of the EMT 
inducers are active during both development and cancer 
progression [35]. Figure  2 is a schematic overview of 
upstream regulators of Snail1/Snail2 and Twist1, and 
their corresponding downstream eﬀ  ects.
Despite its tumour suppressor function in normal 
condi  tions, TGF-β is a potent EMT inducer (Figure 2). It 
has been reported that NMuMG cells, a mouse mammary 
gland epithelial cell line, undergo EMT upon TGF-β 
treatment [36]. Th   e phosphorylated Smad proteins trans-
locate to the nucleus and control the expression of target 
genes [2]. Smads have low aﬃ   nity for DNA and interact 
with DNA-binding cofactors to gain high aﬃ   nity  and 
selectivity for speciﬁ   c target genes [37]. Co-immuno-
precipitation and chromatin immunoprecipita  tion 
experi ments  identiﬁ  ed Snail1 as a cofactor for Smad3/4. 
TGF-β leads to translocation of Snail1 to the nucleus, 
where it interacts with activated Smad3/4. Th  is  complex 
binds the promoters of CDH1 and the Coxsackie- and 
adenovirus receptor (CAR), which have an E-box and a 
Smad-binding element nearby. In vivo, the Snail1-
Smad3/4 complex was found in the nucleus of tumour 
cells at the invasive front [38]. Another protein that 
interacts with the Smads is high mobility group protein 
A2 (HMGA2), a non-histone chromatin binding factor 
containing three A/T hook domains, which enable it to 
bind to A/T-rich sequences in the minor groove of DNA 
[39]. In mammary epithelial cells, TGF-β induces HMGA2 
via the Smad pathway [40]. In turn, HMGA2 binds the 
SNAI1 promoter in cooperation with Smads and induces 
SNAI1 expression, CDH1 repression, and TGF-β-induced 
EMT. HMGA2 acts as a speciﬁ  c regulator of Snail1 and 
possibly also of Twist1, Snail2, ZEB1 and ZEB2, probably 
by general chromatin reorganisation and DNA binding of 
the A/T hook domains [41].
A novel upstream regulator of Snail1 is Ladybird 
homeo  box 1 (LBX1), a transcription factor implicated in 
normal myogenesis and neurogenesis. LBX1 over  expres-
sion in MCF-10A cells elicits EMT, enhances migration, 
and increases the CD44+/CD24- population. A consider-
able increase of endogeneous mRNA levels of TGF-β2, 
SNAI1 and ZEB1/2 was observed, and promoter analysis 
proved that LBX1 directly activates the SNAI1 and ZEB1 
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immunohistochemistry, LBX1 expression was associated 
with triple-negative basal-like tumours [42].
Th   e role of mammalian Y-box binding protein-1 (YB-1) 
in breast tumorigenesis is well studied. Elevated YB-1 
expression in mammary glands causes chromosomal 
instability and induces breast carcinomas in lactating 
transgenic mice [43], whereas YB-1 overexpression in 
MCF7 adenocarcinoma cells enhances their proliferation 
and formation of colonies in soft agar [44]. YB-1 is 
involved in fundamental processes, such as DNA repair, 
mRNA transcription, splicing, translation and stabilisa-
tion [45]. Overexpression of YB-1 in H-Ras-transformed 
MCF-10A cells induces EMT accompanied by enhanced 
metastatic potential and decreased proliferation rates, 
but the cells fail to form tumours in vivo. Microarray 
gene analysis revealed that YB-1 increases TWIST1 
expression on the transcriptional and translational levels 
and directly activates cap-independent translation of 
Snail1 mRNA. In vivo, YB-1 expression was associated 
with potentially metastatic breast cancer cells and poor 
clinical outcome and was inversely correlated with CDH1 
expression levels in breast cancer specimens [46].
From a recent screening of an RNA interference library 
in cells defective in the early steps of metastasis (migra-
tion and invasion), KLF17 was identiﬁ  ed as a metastasis 
suppressor in human breast cancer. Loss of KLF17 leads 
to metastasis through direct regulation of Id1. Moreover, 
an inverse correlation was found between KLF17 and Id1 
expression in human breast cancer samples. Th  is 
relation  ship can potentially be used to predict the meta-
static state of primary breast cancer [47].
Steroid receptor coactivator-1 (Src-1) and hypoxia-
induci  ble factor-1α (HIF-1α) are newly discovered 
Figure 2. Snail1 and Twist1 contribute to a series of normal processes and cancer related progression in the mammary gland. Snail1 and 
Twist1 contribute to diff  erent developmental and pathological outcomes in the mammary gland. Several epithelial-to-mesenchymal transition 
(EMT)-inducing signals in breast epithelial cells induce Snail1 and Twist1 transcription factors. Examples of eff  ector or direct target genes that are 
regulated by Snail1 and Twist1 to produce the indicated outcomes are shown. Note that in many cases numerous targets that mediate a specifi  c 
outcome have been identifi  ed, but only one example target or eff  ector gene is shown here. AKT2, v-akt murine thymoma viral oncogene homolog 
2; CAR, coxsackie virus and adenovirus receptor; HIF-1α, hypoxia inducible factor-1 alpha; IL-6, interleukin-6; LBX1, ladybird homeobox 1; MiR-
10b, microRNA-10b; NF-κB, nuclear factor-κB; p21, cyclin dependent kinase inhibitor 1A; p16, cyclin dependent kinase inhibitor 2A; Src-1, steroid 
receptor co-activator-1; TGF-β, transforming growth factor-beta; TNF-α, tumour necrosis factor-alpha; TrkB, neutrophic tyrosine kinase receptor; Wnt, 
wingless-type MMTV integration site family; YB-1, Y-box binding protein 1; ZEB1, zinc fi  nger E-box-binding homeobox.
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promotes transcription by interacting with nuclear 
receptors and transcription factors. Src-1 is strongly 
expressed in HER-2-positive breast cancers and corre-
lates with disease recurrence and resistance to endo-
crine therapy [50]. Together with PEA3 (polyomavirus 
enhancer activator 3), Src-1 binds to and co-activates 
the proximal TWIST1 promoter, enhan  cing breast 
cancer invasiveness and metastasis [48]. It has been 
reported that HIF-1α induces Snail1, ZEB1, ZEB2 and 
E47 [51,52]. HIF-1α and TWIST1-null mice show 
phenotypic similarities, which points to a possible link 
between these genes [8,53]. Th   is suggestion is supported 
by studies showing that HIF-1α can bind and activate 
the  TWIST1 promoter via the hypoxia-response 
element. Th  is might represent an early step and a 
critical mechanism causing hypoxia-induced tumour 
progression and metastasis [49].
Snail1 and Twist1: potent protection against 
anoikis and senescence
Mounting experimental evidence indicates that the 
Snail1 and Twist1 transcription factors control cell 
prolifera  tion and survival, which has major consequences 
for cancer progression. In fact, upregulation of Snail1 
could be a rapidly induced epigenetic variation aimed at 
genetically inhibiting cell death. Indeed, expression of 
Snail1 seems to protect cells from caspase-mediated 
programmed cell death elicited by serum depletion or by 
signals downstream of therapeutic agents, TNF-α, and 
DNA damage [54,55]. In this context, it is worth 
mention  ing that the highly homologous Snail2 gene 
seems to be a target of p53 and acts as an antagonist of 
PUMA (p53-upregulated modulator of apoptosis) [56]. 
Like Snail1, Twist1 also seems to be able to regulate 
resistance of breast cancer cells to chemotherapeutics 
such as paclitaxel. Twist1 transactivates AKT2, which 
results in increased survival, migration and invasiveness 
[57]. Furthermore, chemotherapeutic treatment of breast 
cancer cells with adriamycin results in upregulation of 
Twist1 and its interaction with p53-MDM2. Only the 
cells undergoing EMT display enhanced invasiveness and 
multidrug resistance [58]. Twist1 and Snail1 seem to play 
a central role in the metastasis induced by TrkB, a 
neutro  phic tyrosine kinase receptor, mainly by suppres-
sing anoikis [59]. Furthermore, Twist proteins were 
recently found to be responsible for bypassing ErbB2 or 
Ras oncogene-induced senescence. Th  is is explained at 
least in part by Twist proteins repressing both trans-
cription of p21CIP1 (in a p53-independent manner) and 
p16Ink4a [60]. Th   ese results indicate that Snail1 and Twist 
proteins have a doubly damaging eﬀ  ect with potent pro-
survival functions that, in conjunction with EMT, provide 
an explanation for the strong contribution towards 
tumour progression. Th  e relationships between Snail1, 
Twist1 and AKT2, TrkB, p21 and p16 are depicted in 
Figure 2.
Snail1 and Twist1 under control of the tumour 
micro-environment
In addition to the role played by the induction of EMT by 
growth factors and developmental signalling pathways in 
cancer progression, the tumour micro-environment is 
involved as well. Th  e inﬂ   ammatory tumour micro-
environ  ment evolves as tumours grow, with inﬁ  ltration of 
immune cells and activation of the inﬂ  ammatory 
responses. Inﬂ  ammatory cells, particularly tumour-asso-
ciated macrophages (TAMs), are usually found at the 
invasive front of more advanced tumours [61]. TAMs 
facilitate angiogenesis, ECM breakdown and tissue 
remodel  ling, and thereby they promote tumour cell 
motility. TAMs also secrete pro-inﬂ  ammatory cytokines, 
such as TNF-α. Wu and colleagues [62] demonstrated 
that Snail1 can be stabilised by TNF-α through the 
activa  tion of the NF-κB pathway. TNF-α and NF-κB 
induce the COP9 signalosome 2 (CSN2), the second and 
most conserved subunit of the COP9 signalosome, which 
inhibits ubiquitination and degradation of Snail1. Th  ese 
researchers also showed that knockdown of Snail1 
suppresses both intrinsic and inﬂ  ammation-enhanced 
migration, which provides a plausible mechanism for 
inﬂ   ammation-induced metastasis [62]. Another study 
focused on IL-6, a pleiotropic cytokine that participates 
in acute inﬂ  ammation [63]. Elevation of serum IL-6 has 
already been shown to be correlated with advanced 
breast tumour stage, metastasis and poor prognosis 
[64,65]. MCF7 cells that constitutively express IL-6 
exhibit an EMT phenotype characterised by upregulation 
of Snail1 and Twist1. Alternatively, they also observed 
that MCF7 cells overexpressing Twist1 produce more 
IL-6 due to aberrant activation of STAT3 (signal 
transducer and activator of transcription 3), which 
illustrates the role of IL-6 in breast cancer progression 
and eventually in metastasis [63].
Th  ere is a strong association between inﬂ  ammation 
and tumorigenesis. In inﬂ  ammatory diseases, NF-κB is 
one of the key pathways generating a loop that maintains 
the inﬂ  ammatory signals by inducing a wide range of 
pro-inﬂ   ammatory cytokines, chemokines and growth 
factors. Th  e recruitment of immune cells, TAMs and 
cancer-associated ﬁ   broblasts producing NF-κB and 
HIF-1α generates a micro-environment capable of driv-
ing tumour progression. In cancer development, NF-κB 
is linked to resistance to apoptosis and increased angio-
genesis [66]. Although TGF-β is described as an anti-
inﬂ  ammatory cytokine, it contributes to the formation of 
cancer-associated ﬁ   broblasts via the activation of 
resident ﬁ  broblasts. TGF-β is the most potent inducer of 
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pro-inﬂ  ammatory interleukins [66].
Besides inﬂ   ammatory cytokines, matrix metallo-
proteinases (MMPs) are also important participants in 
tumour progression because they degrade structural 
components of the ECM, which allows tumour invasion 
and metastasis. In breast tumours, MMP-3 is frequently 
upregulated. It can induce Snail1 expression and EMT 
through increased production of cellular reactive oxygen 
species. MMP-3-induced EMT causes DNA damage and 
genomic instability [67].
Snail1 and Twist1 contribute to EMT and breast 
cancer stemness
Relapse and subsequent metastatic spread to distant sites 
is the main cause of cancer death. Nevertheless, meta-
stasis formation is considered an ineﬃ   cient  process 
because thousands of cancer cells are shed into the 
circula  tion, but only a few cells can survive, reach 
secondary organs, and colonise them [68]. Th   ere is recent 
growing interest in one particular cell population of so-
called cancer stem cells (CSCs) because they could be 
responsible for therapy failure and cancer recurrence. 
Stem cell features include self-renewal, ability to 
diﬀ  erentiate, and resistance to chemotherapeutic drugs 
and radiation [69]. CSCs were ﬁ  rst  identiﬁ   ed in the 
hematopoietic system [70], and more recently they were 
also described in solid tumours of breast, colon and brain 
[71,72]. Al-Hajj and colleagues [71] initially described the 
CD44+/CD24-/low phenotype as a feature of human breast 
CSCs. Th   is cell population, which was fractionated from 
a primary invasive breast cancer and metastatic pleural 
eﬀ  usions, has classical features of normal stem cells and 
can form tumours in immunocompromised nonobese 
diabetes/severe combined immunodeﬁ  ciency  (NOD/
SCID) mice. Th  e  CD44+/CD24- population is associated 
with the expression of basal/mesenchymal or myoepi-
thelial markers and is enriched in basal-like and BRCA1 
mutant breast cancers [71]. Th  e origin of breast CSCs 
(BCSCs) is still unclear. One hypothesis is that BCSCs are 
derived from transformed, resident tissue stem cells, 
which occasionally produce a copy of themselves but 
most often generate daughter cells with limited tumori-
genicity. Alternatively, CSCs might be derived from 
transformed, diﬀ   erentiated epithelial cells that acquire 
stem cell charac  teristics. Recurrence of cancer after 
therapy suggests that treated patients still have a small 
population of tumorigenic CSCs [69]. Th   e cellular trans-
formations needed for resistance show similarities to 
some changes required for the acquisition of a more 
aggressive pheno  type. In this respect, several studies link 
EMT with CSCs and therapy failure.
Th  e Wnt signalling pathway is also thought to be 
necessary for cancer cell self-renewal. Th  e  triple-negative 
SUM1315 cancer cell line is known for its strong Wnt 
activity and its ability to metastasise to the lung in mice 
[73]. Th  is cell line exhibits a CD44+/CD24- proﬁ  le and 
strong expression of SNAI2 and TWIST1. Inhibition of 
the Wnt pathway increases the CD44-/CD24- population 
and blocks tumour formation because Snail2 and Twist1 
levels are decreased and expression of epithelial markers 
is increased [68]. Further studies are needed to determine 
if therapies targeting the Wnt pathway will aﬀ  ect tumour 
recurrence and/or metastasis.
A novel subtype of breast cancer was recently des-
cribed, namely metaplastic breast cancers (MBCs), which 
are aggressive, chemoresistant tumours associated with 
poor outcome. MBCs are frequently triple-negative and 
express basal epithelial markers. Based on an integrated 
genomic-proteomic approach, MBCs represent an 
indepen  dent subtype that is distinct from basal-like 
cancers. Th   eir transcriptional proﬁ  les are closely related 
to claudin-low cancers [74]. Claudin-low cancers are a 
novel subgroup of receptor-negative breast cancers 
charac  terised by loss of genes involved in cell-cell 
adhesion and strong expression of mesenchymal markers 
such as vimentin [75]. It has been reported that the gene 
expression patterns of CD44+/CD24- cells showed a 
signiﬁ   cant correlation with the claudin-low subgroup. 
More  over, residual cancer cells after conventional 
therapy are the tumour-initiating cells that could be more 
resistant and have more mesenchymal-like features, 
which are characteristics of claudin-low tumours [76]. 
Additionally, claudin-low tumours and MBCs are 
enriched in stem cell-like markers (high CD44/CD24 and 
CD29/CD24 ratios) and EMT markers (strong SNAI2 
and TWIST1 expression in MBCs and strong SNAI3 in 
claudin-low tumor cells) [74].
Assuming that metastasis requires dissemination of 
tumour stem cells or tumour cells undergoing EMT, it 
seems likely that such cells should be detectable among 
circulating tumour cells (CTCs) found in breast cancer 
patients. Patient blood samples positive for CTCs were 
analysed for EMT markers (Twist1, Akt and PI3Kα) and 
the BCSC marker aldehyde dehydrogenase 1, a detoxify-
ing enzyme responsible for the oxidation of intracellular 
aldehydes [77]. Expression of the EMT markers and 
aldehyde dehydrogenase 1 was correlated with poor res-
ponse to breast cancer-related therapies. A major propor-
tion of CTCs of MBC patients shows EMT and tumour 
stem cell features, which is indicative of therapy-resistant 
cell populations. Detection and characterisation of CTCs 
exhibiting EMT or stem cell-like metabolism might be a 
powerful diagnostic tool for patient stratiﬁ  ca  tion, early 
identiﬁ  cation of therapy failure, or the poten  tial risk of 
resistance to a given thera  peutic intervention [77].
Th  e relationship between EMT and CSCs has been 
studied as well. Mani and colleagues [78] proposed that 
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like stem cells isolated from normal or neoplastic cell 
populations. When SNAI1 and TWIST1 were expressed 
in human mammary epithelial cells (HMLEs), Her2/neu-
transformed HMLEs, and  V12H-Ras-transformed 
HMLEs, the cells went through EMT and acquired a 
greater mammosphere-forming ability and a CD44+/
CD24- expression pattern. Although these enriched 
CD44+/CD24- cells were considered as stem cells, tumour 
formation  in vivo was only observed in V12H-Ras-
transformed HMLEs upon overexpression of SNAI1 or 
TWIST1 [78]. Comparable ﬁ   ndings were reported by 
Morel and colleagues [79], which demonstrates that 
CSCs can develop from HMLEs upon aberrant activation 
of the Ras/mitogen-activated protein kinase pathway.
Epithelial-to-mesenchymal transition and 
microRNAs
In the past few years, considerable evidence has shown 
that small RNA species are involved in the control of RNA 
stability or translation. MicroRNAs (miRNAs) are involved 
in physiological processes, such as muscle diﬀ  erentiation, 
and in the onset and/or progression of several pathologies, 
such as cancer. More than 50% of human miRNAs are 
located in fragile chromosomal regions that are prone to 
mutations during tumour develop  ment [80]. Functional 
characterisation revealed that miRNAs can act as 
oncogenes (miR-21, miR-155, miR-17-92 cluster) or as 
tumour suppressor genes (miR-34a, let-7) by silencing 
target genes encoding tumour-suppressors or oncogenic 
proteins, respectively [80].
Th   e miR-200 family consists of two subgroups located 
on chromosomes 1 (miR-200b, miR-200a and miR-429) 
and 12 (miR-200c and miR-141) and predicted to target a 
large common group of genes [81]. Expression of the 
miR-200 family is enriched in diﬀ  erentiated  epithelial 
tissues. Several studies have demonstrated an inverse 
correlation between expression of the miR-200 family 
and the ZEB transcription factors [82,83]. Suppression of 
endogeneous miR-200 family members is suﬃ   cient  to 
induce EMT, whereas their ectopic expression induces 
MET in normal and cancer cell lines through direct 
targeting of ZEB1/2 [83]. miRNA screening in human 
breast cancer revealed metastatic suppressor miRNAs 
(miR-335, miR-126) [84] and pro-metastatic miRNAs 
(miR-10b, miR-373, miR-520c) [85,86]. It was shown that 
miR-10b was needed for in vitro invasiveness and in vivo 
metastasis. Twist1 could bind and activate the MIR10B 
promoter, leading to upregulation of the pro-metastatic 
gene  RHOC and to the translational inhibition of 
HOXD10, an inhibitor of genes involved in cell migration 
and ECM remodelling [86]. Growing evidence shows the 
importance of miRNAs in stem cells and CSCs. Th  e 
embryonic stem cell factors Oct4, Nanog and Sox2 can 
occupy the promoters of many transcription factors and 
the regulatory sequences of 14 miRNAs [87]. Moreover, 
embryonic stem cells deﬁ   cient in miRNA processing 
enzymes had a diminished capacity for diﬀ  erentiation 
and self-renewal [88]. Isolation of tumour-initiating cells 
from breasts of patients before and after chemotherapy 
indicated that after chemotherapy these cells were 
resistant to drugs and did not express let-7 and miR-200 
family members. Experiments proved that these miRNAs 
were upregulated when diﬀ   erentiation was favoured, 
indicating that stem-like cancer cells lack expression of 
both the let-7 and miR-200 families [89]. Some of the 
predicted targets of the miR-200 family members, such 
as Sox2, KLF4 and the polycomb repressor Bmi1, are 
involved in maintaining or inducing the stem cell pheno-
type [90,91]. It has been shown that miRNAs in 
pancreatic and colorectal cancer cells can control stem-
ness properties. Strong ZEB1 expression was associated 
with Bmi1 overexpression in undiﬀ  erentiated  tumour 
cells while Bmi1 was negatively regulated by miR-200 
family members (particularly miR-200c) and by miR-203, 
and to a lesser extent by miR-183, the so-called stemness-
inhibiting miRNAs [92]. It was also recently shown that 
normal mammary stem cells and breast cancer stem cells 
with reduced expression of miR-200 family members had 
elevated Bmi1 expression [93].
Conclusion
Breast cancer, the most common cancer among women, 
is a heterogeneous disease in terms of tumour histology, 
clinical presentation and response to therapy. Because 
metastatic spread of tumour cells is responsible for 
almost all breast cancer deaths, considerable interest has 
grown in gaining a full understanding of the molecular 
processes in order to develop risk assessment schemes 
and suitable markers for evaluating the eﬃ   cacy  of 
therapy. EMT is the biological morphogenetic process by 
which epithelial cells undergo morphological changes by 
losing their epithelial characteristics and gaining mesen-
chymal features. Th  e switch in certain diﬀ  erentiation 
markers is accompanied by functional changes required 
for cells to migrate and invade the ECM. In pathological 
conditions, EMT is considered as the reactivation of a 
developmental process controlled by a network of trans-
criptional regulators. Accumulating evidence supports 
the notion of a relationship between key EMT molecules 
such as Snail1 and Twist1 and bad cancer prognosis, 
resistance to chemotherapy and the initiation of the early 
steps of metastasis. Interest has been growing in 
investigating the importance of inﬂ  ammation  during 
tumorigenesis. Inﬂ  ammatory signals produced by NF-κB, 
HIF-1α and TGF-β recruit immune cells, TAMs and 
cancer-associated ﬁ  broblasts, which generates a micro-
environment that drives cancer progression. Moreover, 
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might link EMT to stemness. Cancer stem cells are 
believed to be responsible for therapy failure and cancer 
recurrence. Knowing the molecular signature of the EMT 
program would help to understand the complexity of 
these diﬀ  erent features. Th   is might eventually open new 
avenues to the development of targeted therapies to 
restore the epithelial state and immunocompetence in 
order to decrease the rate of death from breast cancer.
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